ArticleBMC musculoskeletal disorders2025
Associations of serum bile acids and amino acids with low skeletal muscle mass among Chinese population: a cross-sectional study.
Article in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundSarcopenia, characterized by progressive muscle loss, burdens aging populations. While bile acids (BAs) in skeletal muscle mass (SMM) are poorly understood, the role of amino acids (AAs) remains debated. This study investigated the associations between serum BAs, AAs, and low SMM in Chinese adults.
methodsAmong 2170 initially enrolled participants, 702 were finally analyzed. Participants were classified into low and normal SMM groups. Serum BAs and AAs were quantified by targeted LC-MS/MS. Nonlinear relationships were assessed using restricted cubic spline analysis. Mediation analysis was used to assess the mediating effects of metabolic factors.
resultsThe prevalence of low SMM was 14.5% (females: 21.1% vs. males: 10.2%). Multivariable logistic regression identified that increased glycocholic acid (GCA, OR = 0.561, p = 0.030), glycolithocholic acid (GLCA, OR = 0.255, p < 0.001) and deoxycholic acid (DCA, OR = 0.444, p = 0.003) were independently associated with lower risk of low SMM in the fully adjusted model. Valine (OR = 0.646, p = 0.010) and leucine (OR = 0.680, p = 0.024) showed consistent protective effects against low SMM at physiological concentrations. Mediation analysis showed BMI mediated protective effects of GCA, valine and leucine (all p < 0.01), while creatinine/cystatin C ratio mediated leucine's effect (p = 0.030). Notably, GLCA exhibited direct protection independent of metabolic mediators (both p < 0.01).
conclusionsThis study identified specific BAs and AAs significantly correlated with preserved SMM, suggesting that modulating BA metabolism (particularly elevating GLCA) and maintaining optimal BCAA levels may be effective strategies for low SMM. GLCA's direct protective effect supports exploring dietary or microbiota-targeted interventions. Individual metabolic profiles, such as BMI, should be incorporated into personalized sarcopenia management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.